Gsa Capital Partners LLP Unity Biotechnology, Inc. Transaction History

Gsa Capital Partners LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.56 - $1.29 $47,188 - $108,701	-84,265 Reduced 11.64%	639,937 $361,000
Q1 2022 May 11, 2022	BUY	$0.72 - $1.86 $20,222 - $52,241	28,087 Added 4.03%	724,202 $811,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $297,367 - $725,118	228,744 Added 48.94%	696,115 $1.02 Million
Q3 2021 Nov 12, 2021	BUY	$2.91 - $4.5 $760,932 - $1.18 Million	261,489 Added 127.01%	467,371 $1.4 Million
Q2 2021 Aug 05, 2021	BUY	$4.15 - $6.3 $854,410 - $1.3 Million	205,882 New	205,882 $955,000
Q4 2020 Feb 03, 2021	SELL	$3.42 - $6.36 $104,101 - $193,592	-30,439 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$2.94 - $12.43 $89,490 - $378,356	30,439 New	30,439 $105,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $14M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.